ADVANCE-ID Network

What ADVANCE-ID Network does

ADVANCE-ID (Advancing Clinical Evidence in Infectious Diseases) is a Singapore-based clinical research network headquartered at the National University of Singapore's Saw Swee Hock School of Public Health. Established in March 2022 with a multi-million dollar grant from the Wellcome Trust and co-funding from NUS, NTU, Duke-NUS, NCID, and SCRI, the network was officially launched in February 2023. It operates 60 active clinical trial and surveillance sites across 20 countries, with a reported 10,962+ patients enrolled across studies as of the latest updates.

The network's research portfolio spans four interconnected programmes: the RAPID Phase 4 trial linking rapid bacterial identification and resistance gene detection to targeted antibiotic administration for hospital-acquired infections; TREAT-GNB, an adaptive platform trial using a novel PRACTical (Personalised Randomised Controlled Trial) design to evaluate treatments for severe multidrug-resistant Gram-negative infections; ACORN-HAI, a clinically-oriented antimicrobial resistance surveillance system for healthcare-associated infections aligned with WHO GLASS; and DETECT, a regional initiative strengthening microbiology laboratory diagnostics through gap analysis, LIMS implementation, and rapid diagnostic testing. Supporting infrastructure includes public engagement regional hubs in Malaysia, Taiwan, and Thailand, a PhD programme, the MODRA postdoctoral academy, and peer-reviewed publications in The Lancet, Nature Microbiology, and JAMA.

ADVANCE-ID operates as a not-for-profit research consortium funded by grants, institutional co-funding, and industry clinical trial agreements with pharmaceutical and biotechnology companies developing novel antimicrobial agents. Its revenue streams comprise the Wellcome Trust grant, institutional co-funding from Singapore academic partners, and fees from industry-sponsored Phase II/III trials designed to generate FDA/EMA submission-quality data in high-burden AMR regions. Distribution is conducted through direct engagement with pharmaceutical companies and through hospital network partnerships across Asia.

Name

ADVANCE-ID Network

Legal name

ADVANCE-ID

Website

https://advance-id.network

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

ADVANCE-ID is a Singapore-based, NUS-affiliated not-for-profit clinical research network operating 60+ active sites across 20 countries to conduct antimicrobial resistance trials, surveillance, and diagnostics strengthening for pharmaceutical sponsors and hospitals in Asia.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Healthcare-Associated Infection (HAI) & Antimicrobial Resistance (AMR) Surveillance (HLAJABAH)

akta.pro secondary industries

Disease Surveillance, Epidemiology & Outbreak Response (BPAIAJAA), Hospital Epidemiology & Infection Prevention (HLAKAGAF), Infectious Disease Program Evaluation (e.g., HIV/TB/Malaria/STIs) (HLAJANAF)

Keywords

• Clinical trials network
• Antimicrobial resistance research
• Infectious disease surveillance
• Clinical research services
• Hospital epidemiology studies

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

1. Wellcome Trust Grant: ADVANCE-ID was established with a multi-million dollar grant from the Wellcome Trust to conduct clinical trials for AMR therapeutics. This constitutes the primary funding mechanism for the network's operations.
2. Institutional Co-funding: Co-funding from institutional partners including NUS Saw Swee Hock School of Public Health, NUS Yong Loo Lin School of Medicine, Duke-NUS Medical School, NTU Lee Kong Chian School of Medicine, National Centre for Infectious Diseases (NCID), and Singapore Clinical Research Institute (SCRI).
3. Industry Clinical Trial Agreements: Revenue from pharmaceutical/biotech companies for conducting Phase II/III clinical trials in the network. Companies may co-contribute financially depending on trial complexity, with additional funding required for Phase III trials involving other geographic locations or networks.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels10 records

Core offering

ADVANCE-ID (Advancing Clinical Evidence in Infectious Diseases) is a clinical trials and surveillance network comprising over 100 hospitals across Asia, based at the National University of Singapore. The network conducts Phase II–IV clinical trials (e.g., RAPID Trial, TREAT-GNB adaptive platform trial) and large-scale healthcare-associated infection surveillance (ACORN-HAI) focused on antimicrobial resistance (AMR), supported by diagnostic strengthening (DETECT), public engagement, and training programmes.

Product overview

ADVANCE-ID (Advancing Clinical Evidence in Infectious Diseases) is a clinical trials and surveillance network comprising over 100 hospitals across Asia, based at the National University of Singapore. The network operates as a unified research platform focused on antimicrobial resistance, offering multiple interconnected products and services. The core clinical trials include RAPID Trial (phase 4 rapid diagnostics intervention study) and TREAT-GNB (adaptive platform trial for Gram-negative bacterial infections). Surveillance capabilities are anchored by ACORN-HAI (healthcare-associated infection surveillance network) and DETECT (diagnostics strengthening programme). These are supported by public engagement initiatives including the REACH Asia Forum and a structured Public Engagement Project. Educational offerings comprise a PhD Programme, Seminar Series, and MODRA training academy. The network also produces the Bacterial and Fungal Infections Newsletter and publishes research through its Publications Programme. Together, these products form an integrated ecosystem for clinical research, surveillance, capacity building, and knowledge dissemination in infectious diseases across Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• RAPID Trial

Quantifiable outcome

• 10,962+ patients enrolled across ADVANCE-ID studies
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

13 partnerships are on record, tiered core, flagship and supporting.

• CARB-XcoreStrategic or Co-development Partner · 19 November 2025CARB-X is a global non-profit partnership dedicated to combating drug-resistant bacteria. ADVANCE-ID is aligned with CARB-X's mission and eligibility criteria for 2025 funding rounds targeting Gram-negative pathogens and Salmonella Typhi diagnostics. CARB-X representatives (Betsy Trainor) serve on ADVANCE-ID's DETECT Scientific Advisory Board.
• Infex TherapeuticscoreStrategic or Co-development Partner · 21 May 2025Memorandum of Understanding signed between ADVANCE-ID and Infex Therapeutics to investigate hospital-acquired drug-resistant infections in Asia. Infex is developing MET-X, a metallo-beta-lactamase (MBL) inhibitor that restores antibiotic activity against MBL-producing bacteria. The collaboration will design and deliver clinical trials exploring MET-X alongside existing licensed therapies to target carbapenem-resistant MBL-producing organisms across ADVANCE-ID's network of over 100 hospitals in Asia.
• World Health Organization (WHO)flagshipStrategic or Co-development Partner · 18 June 2024ADVANCE-ID participates in WHO's Global Clinical Trials Forum (GCTF), contributing to building sustained clinical research capacities, improving ecosystem efficiencies, and enabling adoption of innovations globally. Prof Li Yang Hsu represented ADVANCE-ID at the GCTF stakeholder consultation. ADVANCE-ID also aligns its ACORN-HAI surveillance with WHO Global Antimicrobial Resistance and Use Surveillance System.
• National University of Singapore (NUS)coreStrategic or Co-development Partner · 10 March 2023ADVANCE-ID's operational headquarters is located at NUS Saw Swee Hock School of Public Health. NUS provides institutional support through multiple schools including Yong Loo Lin School of Medicine, and faculty members serve in key leadership roles including Director, Vice Dean, and Principal Investigators.
• Duke-NUS Medical SchoolsupportingStrategic or Co-development PartnerContributing institutional partner providing clinical research expertise and faculty involvement in ADVANCE-ID network activities.
• Nanyang Technological University (NTU) Lee Kong Chian School of MedicinesupportingStrategic or Co-development PartnerContributing institutional partner with faculty representation on ADVANCE-ID's Governing Board (A/Prof Yeo Tsin Wen).
• National Centre for Infectious Diseases (NCID)supportingStrategic or Co-development PartnerSingapore-based national infectious diseases centre providing clinical research infrastructure, staff support (SCRN/IDRTO), and institutional partnership in the ADVANCE-ID network.
• Singapore Clinical Research Institute (SCRI)supportingImplementation/ SI/ Consulting PartnerSCRI supports the implementation of the ADVANCE-ID network through clinical research infrastructure and operational expertise, including ACORN-HAI eLearning Platform hosting.
• Mahidol-Oxford Tropical Medicine Research Unit (MORU)supportingStrategic or Co-development PartnerInternational research unit contributing to ADVANCE-ID's network through Prof Nicholas Day's participation on the Governing Board and collaborative research programmes including MODRA (MORU-OUCRU Discovery Research Academy).
• Oxford University Clinical Research Unit (OUCRU)supportingStrategic or Co-development PartnerCollaborative research partner contributing through Prof Guy Thwaites' Governing Board membership and joint MODRA programme for early-to-mid career researchers in South and Southeast Asia.
• ECRAID (European Clinical Research Alliance for Infectious Diseases)supportingStrategic or Co-development PartnerEuropean counterpart clinical research network for infectious diseases, contributing to ADVANCE-ID's ecosystem of global AMR research collaboration.
• PREPARE (Platform for European Preparedness Against Re-emerging Infectious Diseases)supportingStrategic or Co-development PartnerEuropean research preparedness network collaborating with ADVANCE-ID on infectious disease research and surveillance capabilities.
• Garuda Clinical Research Network (Implicit in regional hub structure)supportingStrategic or Co-development PartnerRegional clinical research networks across Asia including but not limited to networks in Malaysia, Taiwan, Thailand, Vietnam, Nepal, Pakistan, and Philippines participating in ADVANCE-ID surveillance and trial activities.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• ARLG (Antibacterial Resistance Leadership Group): US-based NIH-funded clinical research network conducting clinical trials to address antibacterial resistance. ARLG performs a comparable function to ADVANCE-ID in North America, including Phase II/III AMR trials, surveillance studies, and adaptive trial designs, serving as the regional counterpart.
• GARDP (Global Antibiotic Research & Development Partnership): Global non-profit accelerating development of treatments for drug-resistant infections. Dr Mo Yin consults for GARDP, indicating direct ecosystem overlap. Both organisations focus on bringing new antimicrobial agents through clinical development, with GARDP operating at the product-development layer and ADVANCE-ID at the trial-execution layer.
• ECRAID (European Clinical Research Alliance for Infectious Diseases): European clinical research network for infectious diseases that ADVANCE-ID explicitly partners with. ECRAID operates analogous multi-site adaptive trial infrastructure for infectious diseases across Europe, making it the closest geographic-complement peer serving a parallel function in a different region.
• IDCRC (Infectious Diseases Clinical Research Consortium): US NIAID-funded consortium conducting clinical trials for infectious diseases including AMR pathogens. Operates as a comparable multi-site academic clinical trials network with adaptive trial design capabilities, paralleling ADVANCE-ID's structure and mission in a different geography.
• MORU (Mahidol-Oxford Tropical Medicine Research Unit): Thailand-based tropical medicine research unit with Prof Nicholas Day on ADVANCE-ID's Governing Board and joint MODRA programme. MORU conducts large-scale clinical trials on infectious diseases across Asia with similar academic governance and tropical medicine focus.
• OUCRU (Oxford University Clinical Research Unit): Vietnam-based infectious disease research unit with Prof Guy Thwaites on ADVANCE-ID's Governing Board and joint MODRA training programme. OUCRU conducts clinical research on infectious diseases in Southeast Asia with comparable hospital network structure and academic mission.

Broad incumbents

• IQVIA: Global commercial CRO with infectious disease and AMR clinical trial capabilities across geographies including Asia. As a broad incumbent, IQVIA competes for the same pharmaceutical AMR trial sponsors as ADVANCE-ID but operates as a for-profit full-service CRO rather than an academic AMR-specialised network.
• Duke Clinical Research Institute (DCRI): Large US-based academic clinical research organisation with extensive infectious disease and AMR trial capabilities. DCRI is a broader incumbent offering multi-therapeutic CRO services including AMR-relevant trials, but unlike ADVANCE-ID does not specialise in Asia-centric AMR surveillance.

Others

• CARB-X: Global non-profit partnership funding early-stage antibacterial R&D, with CARB-X representative on ADVANCE-ID's DETECT Scientific Advisory Board. CARB-X is a key funder of AMR therapeutics developers that ADVANCE-ID serves as a clinical trial network for, positioning it as a sponsor-ecosystem participant.

Regional players

• PREPARE (Platform for European Preparedness Against Re-emerging Infectious Diseases): European research preparedness network collaborating with ADVANCE-ID on infectious disease research and surveillance. PREPARE operates in a complementary European geography with overlapping clinical research network infrastructure for emerging infectious diseases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ADVANCE__ID
• LinkedInlinkedin.com/company/advance-id

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADVANCE-ID Network